This is achieved by adding fenofibrate to simvastatin.
疗效是通过将非诺贝特加入辛伐他汀里取得的。
Objective: To explore the protective mechanism of fenofibrate on diabetic nephropathy.
目的：探讨非诺贝特对糖尿病肾病的保护机制。
Objective To compare effect of mannose ester and fenofibrate in adjusting hyperlipdemia.
目的比较甘糖酯与非诺贝特的调脂疗效。
AIM To compare the effects of Probucol with polysaccharide sodium (p. s. s) and fenofibrate.
摘要目的：观察比较新药普罗布考片与其它两种降血脂药的降脂作用。
Fenofibrate significantly reduced CVD events in those with low HDL cholesterol or hypertension.
非诺贝特显著降低HDL胆固醇水平较低患者或高血压患者的CVD事件。
Compared with HG group, these changes could be fully or partly reversed by fenofibrate treatment.
与高糖组比较非诺贝特干预后能完全或部分逆转上述变化。
Fenofibrate reversed the effect of ADMA on the expression of MMP-9 and promoted the synthesis of no.
非诺贝特可以抑制adma诱导人脐静脉内皮细胞所致MMP - 9的表达增加并促进NO的合成。
However, the population treated was broader than that recommended by current guidelines for fenofibrate.
但是，受测的人口比目前的非诺贝特推荐人数大得多。
Objective To discuss the val ue of simvastatin plus fenofibrate for the treatment of mixed hyperlipemia.
目的探讨辛伐他汀联合非诺贝特治疗混合性高脂血症的价值。
In ACCORD Lipid, fenofibrate also reduced micro - and macro-albuminuria, markers of diabetic renal disease.
在ACCORD脂质研究基金会，非诺贝特同时降低了微观及宏观尿蛋白量，二者都是胰岛肾病的标志。
Now, we may get that data later this year from the ACCORD trial which is studying fenofibrate in diabetics.
可能在今年晚些时候我们能从ACCORD试验中得到一些数据，这个试验是研究是有关糖尿病患者非诺贝特的使用。
The highest risk and greatest benefits of fenofibrate are seen among those with marked hypertriglyceridemia.
非诺贝特最高风险和最大受益见于伴有明显的高甘油三酯血症患者。
The risk of a first amputation was 36 percent lower among people taking fenofibrate than those taking the placebo.
初次截肢的风险非诺贝特组较安慰剂组降低了36%。
Fenofibrate solid dispersion tablets were prepared by solvent melting method using PEG4000 and sodium lauryl sulfate.
PEG4000十烷硫酸钠体，溶剂-熔融制备非诺贝特固体散体，再适辅混合压片制非诺贝特固体散片。
Conclusion Pioglitazone and fenofibrate have different influences on energy homeostasis and body fat distribution in rats.
结论吡格列酮、非诺贝特对大鼠能量代谢及体脂分布的影响不同。
Objective To observe the effectiveness and safety of atorvastatin combined with fenofibrate in treatment of mixed hyperlipidemia.
目的观察阿托伐他汀联合非洛贝特治疗混合性高脂血症的疗效及安全性。
The study found virtually no difference in the risk for amputations above the ankle between those who did and did not take fenofibrate.
研究发现踝以上截肢风险在服用非诺贝特组和非服用非诺贝特组之间并无显著差异。
Objective To investigate the effects of fenofibrate on E-selectin and intercellular adhesion molecule-1 (ICAM-1) secretion of the endothelial cells.
目的研究非诺贝特对内皮细胞产生E-选择素和细胞间黏附分子1（ICAM-1）的影响。
Objective to investigate the preparation and storage stability of the fenofibrate matrix sustained-release pellets by wet milling and extrusion-spheronization.
目的湿法研磨结合挤出滚圆法制备稳定性良好的非诺贝特骨架型缓释微丸。
The study also confirmed that adding fenofibrate to simvastatin did not result in any excess risk of myopathy (muscle problems), venous thrombosis or pancreatitis.
这项研究同样证实将非诺贝特加入辛伐他汀不会引起任何肌病(肌肉病变)，静脉血栓或胰脏炎等多余危害。
Objective: To investigate the effect of fenofibrate on the expression of adiponectin gene, the level of the plasma adiponectin and endothelial function in diabetic rats.
目的：观察非诺贝特对糖尿病大鼠血脂联素和脂联素基因的表达及内皮细胞功能的干预作用。
The study also found that people in the fenofibrate group had a 47 percent lower risk of amputations below the ankle and without large-vessel disease in the amputated limb.
研究还发现非诺贝特组踝以下截肢风险降低47%，所截肢内无大血管病变。
Conclusion: Fenofibrate can inhibit high glucose-induced proliferation of mesangial cells, decrease synthesis of extracellular matrix, and increase degradation of extracellular matrix.
结论：非诺贝特能抑制高糖培养的系膜细胞增殖，减少胞外基质合成，增加胞外基质的降解。
Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver Disease.
非诺贝特和烟酸对非酒精脂肪肝患者肝内甘油三酯含量，极低密度脂蛋白动力学，胰岛素活性的影响。
Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver Disease.
非诺贝特和烟酸对非酒精脂肪肝患者肝内甘油三酯含量，极低密度脂蛋白动力学，胰岛素活性的影响。
应用推荐